BlissBio
Latest round
- Series B
Last raised
- Jan 2023
Total raised
- $77M
Investors
- 5
About BlissBio
Established in 2017 and based in Hangzhou, China, BlissBio operates as an oncology targeted and immunotherapy drugs developer that provides oncology targeted and immunotherapy drugs. In 2019, the first antibody-drug conjugate (ADC) project enters FDA clinical trial and IND filing stage. The company cooperates with Eisai Morphotek Japan. In December 2022, the company was recognized as a national high-tech enterprise. Ziping Wei, the co-founder and CEO of the company, and she once served as the past president of the Chinese biopharmaceutical technology association of America (CBA).S.S. in genetics from Fudan University. The company provides oncology targeted and immunotherapy drugs. Its product includes product pipeline for antibody-coupled drug ADCs, including BB-1701, BB-1705 and BB-1709. BB-1701 is a HER2 antibody-drug conjugate and it has a marketed drug toxin Eribulin. It technology platforms are divided into four series, which include pre- clinical research platform, process development platform, quality research platform and GMP production platform. Pre- clinical research platform includes design and screening of lead antibodies, small molecule payloads and linkers, and genetic engineering and modification of fixed-point coupled antibodies. Quality research platform adopts high-resolution LC-MS, molecular interaction analyzer, automatic capillary electrophoresis analysis system, UPLC and multi-functional enzyme marker equipment. GMP production platform has passed the quality standard system required by US FDA, EU EMA and China NMPA.
Who invested in BlissBio
5 investors across 3 rounds
See all investors in BlissBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BlissBio
Who invested in BlissBio?
BlissBio has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BlissBio raised?
BlissBio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did BlissBio last raise money?
BlissBio's most recent round on record is a Series B, in Jan 2023.
What does BlissBio do?
Established in 2017 and based in Hangzhou, China, BlissBio operates as an oncology targeted and immunotherapy drugs developer that provides oncology targeted and immunotherapy drugs.
Where is BlissBio headquartered?
BlissBio is headquartered in Hangzhou, China.
Which VCs invest in companies like BlissBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at BlissBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like BlissBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.